Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1984 Oct;26(4):476–480. doi: 10.1128/aac.26.4.476

Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses.

J W Huggins, R K Robins, P G Canonico
PMCID: PMC179947  PMID: 6151377

Abstract

Binary combinations of the N-nucleoside ribavirin (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) and the C-nucleoside analog selenazofurin (2-beta-D-ribofuranosylselenazole-4-carboxamide) or tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide) were tested in vitro for activity against Venezuelan equine encephalomyelitis, Japanese encephalitis, yellow fever, Rift Valley fever, Korean hemorrhagic fever, and Pichinde viruses. The 50% effective dose for each compound alone or in a series of combinations was determined with a plaque reduction assay. Combinations of ribavirin and selenazofurin were synergistic against Venezuelan equine encephalomyelitis, Japanese encephalitis, yellow fever, and Pichinde viruses, with fractional inhibitory concentrations of 0.1, 0.2, 0.4, 0.4, respectively, but showed additive effects against Korean hemorrhagic fever and Rift Valley fever viruses. Combinations of ribavirin and tiazofurin were synergistic against yellow fever and Japanese encephalitis (fractional inhibitory concentrations, 0.41 and 0.48, respectively) but showed additive effects against Korean hemorrhagic fever virus. Combinations of selenazofurin and tiazofurin had additive effects against Japanese encephalitis, yellow fever, and Korean hemorrhagic fever viruses. The effect of combinations on cell toxicity was additive, both in monolayers of nondividing cells incubated under agar for the same period as the plaque assay and for rapidly dividing cells given short-term exposure (4 h), followed by determination of the proportion of surviving cells with a colony forming assay.

Full text

PDF
476

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen L. B., Vanderslice L. K., Fingal C. M., McCright F. H., Harris E. F., Cook P. D. Evaluation of the anti-herpesvirus drug combinations: virazole plus arabinofuranosylhypoxanthine and virazole plus arabinofuranosyladenine. Antiviral Res. 1982 Sep;2(4):203–216. doi: 10.1016/0166-3542(82)90043-2. [DOI] [PubMed] [Google Scholar]
  2. Ayisi N. K., Gupta V. S., Meldrum J. B., Taneja A. K., Babiuk L. A. Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with adenine arabinoside, 5-ethyldeoxyuridine, 5-iododeoxyuridine, and phosphonoacetic acid against herpes simplex virus types 1 and 2. Antimicrob Agents Chemother. 1980 Apr;17(4):558–566. doi: 10.1128/aac.17.4.558. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Berenbaum M. C. A method for testing for synergy with any number of agents. J Infect Dis. 1978 Feb;137(2):122–130. doi: 10.1093/infdis/137.2.122. [DOI] [PubMed] [Google Scholar]
  4. Cooney D. A., Jayaram H. N., Gebeyehu G., Betts C. R., Kelley J. A., Marquez V. E., Johns D. G. The conversion of 2-beta-D-ribofuranosylthiazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase-inhibitory properties. Biochem Pharmacol. 1982 Jun 1;31(11):2133–2136. doi: 10.1016/0006-2952(82)90436-1. [DOI] [PubMed] [Google Scholar]
  5. ELION G. B., SINGER S., HITCHINGS G. H. Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites. J Biol Chem. 1954 Jun;208(2):477–488. [PubMed] [Google Scholar]
  6. Jayaram H. N., Ahluwalia G. S., Dion R. L., Gebeyehu G., Marquez V. E., Kelley J. A., Robins R. K., Cooney D. A., Johns D. G. Conversion of 2-beta-D-ribofuranosylselenazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase-inhibitory properties. Biochem Pharmacol. 1983 Sep 1;32(17):2633–2636. doi: 10.1016/0006-2952(83)90038-2. [DOI] [PubMed] [Google Scholar]
  7. Jayaram H. N., Cooney D. A., Glazer R. I., Dion R. L., Johns D. G. Mechanism of resistance to the oncolytic C-nucleoside 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC-286193). Biochem Pharmacol. 1982 Aug 1;31(15):2557–2560. doi: 10.1016/0006-2952(82)90071-5. [DOI] [PubMed] [Google Scholar]
  8. Jayaram H. N., Dion R. L., Glazer R. I., Johns D. G., Robins R. K., Srivastava P. C., Cooney D. A. Initial studies on the mechanism of action of a new oncolytic thiazole nucleoside, 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193). Biochem Pharmacol. 1982 Jul 15;31(14):2371–2380. doi: 10.1016/0006-2952(82)90532-9. [DOI] [PubMed] [Google Scholar]
  9. Kirsi J. J., McKernan P. A., Burns N. J., 3rd, North J. A., Murray B. K., Robins R. K. Broad-spectrum synergistic antiviral activity of selenazofurin and ribavirin. Antimicrob Agents Chemother. 1984 Oct;26(4):466–475. doi: 10.1128/aac.26.4.466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kirsi J. J., North J. A., McKernan P. A., Murray B. K., Canonico P. G., Huggins J. W., Srivastava P. C., Robins R. K. Broad-spectrum antiviral activity of 2-beta-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent. Antimicrob Agents Chemother. 1983 Sep;24(3):353–361. doi: 10.1128/aac.24.3.353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Robins R. K., Srivastava P. C., Narayanan V. L., Plowman J., Paull K. D. 2-beta-D-Ribofuranosylthiazole-4-carboxamide, a novel potential antitumor agent for lung tumors and metastases. J Med Chem. 1982 Feb;25(2):107–108. doi: 10.1021/jm00344a002. [DOI] [PubMed] [Google Scholar]
  12. Srivastava P. C., Pickering M. V., Allen L. B., Streeter D. G., Campbell M. T., Witkowski J. T., Sidwell R. W., Robins R. K. Synthesis and antiviral activity of certain thiazole C-nucleosides. J Med Chem. 1977 Feb;20(2):256–262. doi: 10.1021/jm00212a014. [DOI] [PubMed] [Google Scholar]
  13. Srivastava P. C., Robins R. K. Synthesis and antitumor activity of 2-beta-D-ribofuranosylselenazole-4- carboxamide and related derivatives. J Med Chem. 1983 Mar;26(3):445–448. doi: 10.1021/jm00357a024. [DOI] [PubMed] [Google Scholar]
  14. Streeter D. G., Witkowski J. T., Khare G. P., Sidwell R. W., Bauer R. J., Robins R. K., Simon L. N. Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc Natl Acad Sci U S A. 1973 Apr;70(4):1174–1178. doi: 10.1073/pnas.70.4.1174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Witkowski J. T., Robins R. K., Sidwell R. W., Simon L. N. Design, synthesis, and broad spectrum antiviral activity of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides. J Med Chem. 1972 Nov;15(11):1150–1154. doi: 10.1021/jm00281a014. [DOI] [PubMed] [Google Scholar]
  16. Zimmerman T. P., Deeprose R. D. Metabolism of 5-amino-1-beta-D-ribofuranosylimidazole-4-carboxamide and related five-membered heterocycles to 5'-triphosphates in human blood and L5178Y cells. Biochem Pharmacol. 1978 Mar 1;27(5):709–716. doi: 10.1016/0006-2952(78)90508-7. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES